VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
KNSA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
KNSAKiniksa Pharmaceuticals International, plc
$95.05$7.2B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
KNSA logo

Kiniksa Pharmaceuticals International, plc

KNSA
NASDAQ · Immunology Biotech
$95.05
At close - Nov 18, 4:00 PM EST - USD
Market Cap$7.24B
P/E73.7x
52W High$99.31
Volume326.55K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q3

ARCALYST Ramp Drives Growth, Regeneron Caps Margins

Kiniksa's quarterly revenue has compounded roughly 163% from $108.6M in 2024Q2 to $286.0M in 2026Q3 on accelerating ARCALYST new patient starts in recurrent pericarditis, with operating margin inflecting from -0.1% to 19.0% and quarterly free cash flow reaching $47.1M on near-zero capital intensity (capex at 0.1% of…

GrowthAccelerating
ProfitabilityModerate
ValuationExpensive
TechnicalsStrong
Explore valuation models
MARKET ACTION

KNSA price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

7/12 Beats

EPS beat 7 of last 12 quarters

02

Valuation risk

+116% Peers

P/E is 116% above peer median

03

Market leadership

RS 96 · Leader

High momentum (Outperforming 96% of market)

04

Strong Uptrend

Strong Trend

Price > 20DMA > 50DMA > 200DMA

Next CatalystEstimated earnings · Jan 27

Market performance

Price History →

Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
KNSA+126.26%
S&P 500 (^GSPC)+6.88%
1-Year Return
KNSA+130.26%
S&P 500 (^GSPC)+10.62%
3-Year Return
KNSA+500.06%
S&P 500 (^GSPC)+58.54%
5-Year Return
KNSA+652.57%
S&P 500 (^GSPC)+59.70%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/EMedian
73.7x
Forward P/EExpansion
64.0x
EV/EBITDA50th %ile
53.5x
FCF YieldCash Flow
2.7%

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
73.7x
55.0x
67th· Fair
EV/EBITDA
53.5x
77.1x
50th· Fair
Price/FCF
36.7x
128.2x
0th· Low
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$2.25-97.6%
Base (Fair)$70.56-26.8%
Bull$9.10-90.4%
$2.25 Bear$70.56 Base$9.10 Bull
Current Market Price: $95.05
Trades at a 34.7% premium to Base DCF ($70.56)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$678M+60.1% YoY
Net income FY25
$59M+236.6% YoY
Free cash flow FY25
$25M+0.0% YoY
Operating margin FY25
11.4%+22.2 pts YoY
ROIC (FY25)17.1%
Avg ROIC 5Y-16.4%
ROE (TTM)17.3%
Piotroski Score6 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate7/12 (58%)
Revenue Beat Rate7/12 (58%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Oct 27, 2026
$0.56+50.9%
vs $0.37
$286M+9.7%
vs $261M
Q3 2026
Jul 28, 2026
$0.30+0.2%
vs $0.30
$244M+7.6%
vs $226M
Q2 2026
Apr 28, 2026
$0.27+50.0%
vs $0.18
$214M+4.0%
vs $206M
Q1 2026
Feb 24, 2026
$0.17-41.4%
vs $0.29
$202M+0.7%
vs $201M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Defense World·1d ago
Kiniksa Pharmaceuticals International, plc $KNSA Stock: Aberdeen Group plc Reduces Stake

Aberdeen Group plc decreased its position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) by 13.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 347,294 shares of the company's stock after selling 56,191 shares during the quarter. Aberdeen

Defense World·3d ago
74,458 Kiniksa Pharmaceuticals International, plc $KNSA Shares Sold by Fisher Asset Management LLC

Fisher Asset Management LLC trimmed its position in Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) by 18.7% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 323,808 shares of the company's stock after selling 74,458 shares during the period. Fisher Asset Management LLC owned about 0.42%

GlobeNewsWire·Nov 11, 2026
Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London

LONDON, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Monday, November 16, 2026 at 11:00 a.m. Greenwich Mean Time (6:00 a.m. Eastern Time).

Zacks Investment Research·Nov 4, 2026
Here's Why Kiniksa Pharmaceuticals International, plc (KNSA) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Filtered for Kiniksa Pharmaceuticals International, plcMore Headlines
04

Compare before deciding

Benchmark KNSA against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Kiniksa Pharmaceuticals International, plc (KNSA)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
KNSA logoKNSAKiniksa Pharmaceuticals International, plcCurrent
$95.05$7.24B73.6760.09%11.58%17.27%—
ARDX logoARDXArdelyx, Inc.
$3.12$770.73M-14.0622.09%-11.85%-35.3%—
PRAX logoPRAXPraxis Precision Medicines, Inc.
$305.19$8.51B-24.78-100%—-29.41%—
RCUS logoRCUSArcus Biosciences, Inc.
$15.76$1.98B-4.51-4.26%-445%-90.04%—
IMVT logoIMVTImmunovant, Inc.
$33.17$6.85B-13.47—-7173.52%-63.01%—
CABA logoCABACabaletta Bio, Inc.
$1.06$172.02M-1.04——-106.78%—

Compare KNSA vs Peers

Kiniksa Pharmaceuticals International, plc (KNSA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ARDX

Most directly comparable listed peer for KNSA.

Scale Benchmark

vs VRTX

Larger-name benchmark to compare KNSA against a more recognizable public peer.

Peer Set

Compare Top 5

vs ARDX, PRAX, RCUS, IMVT

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

KNSA SEC Filings & Documents

Kiniksa Pharmaceuticals International, plc (KNSA) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Oct 27, 2026·SEC

Material company update

Oct 22, 2026·SEC

Material company update

Jul 28, 2026·SEC

10-K Annual Reports

2
FY 2026

Feb 24, 2026·SEC

FY 2025

Feb 25, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

Oct 27, 2026·SEC

FY 2026

Jul 28, 2026·SEC

FY 2026

Apr 28, 2026·SEC

Get notified when KNSA posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

KNSA Frequently Asked Questions

Kiniksa Pharmaceuticals International, plc (KNSA) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Kiniksa Pharmaceuticals International, plc's revenue?

Kiniksa Pharmaceuticals International, plc (KNSA) reported $946.0M in revenue over the trailing twelve months. Revenue was $677.6M in fiscal year 2025.

How fast is Kiniksa Pharmaceuticals International, plc growing?

Kiniksa Pharmaceuticals International, plc (KNSA) grew revenue by 58.2% over the trailing twelve months, compared with the twelve months before.

Is KNSA profitable?

Yes. Kiniksa Pharmaceuticals International, plc (KNSA) earned $109.6M in net income over the trailing twelve months (a 11.6% net margin).

Dividend & Returns
What is KNSA's return on equity?

Kiniksa Pharmaceuticals International, plc (KNSA) had a return on equity (ROE) of 17.3% over the trailing twelve months. That is above the market's typical 10-15%.

What is Kiniksa Pharmaceuticals International, plc's free cash flow?

Kiniksa Pharmaceuticals International, plc (KNSA) generated $197.2M in free cash flow over the trailing twelve months.

What if you invested $1,000 in KNSA back in 2016?

Total return calculator · dividends reinvested · 10+ years of data

See returns →